Quick Answer
Semaglutide and tirzepatide have similar overall GI side effect rates at doses producing comparable weight loss. SURPASS-2 compared tirzepatide (5, 10, 15mg) against semaglutide 1mg in type 2 diabetes patients. Nausea rates were 12 to 23% for tirzepatide versus 18% for semaglutide 1mg. The side effect profiles differ in character: semaglutide tends toward more constipation, while tirzepatide may produce more diarrhea. Neither is clearly better tolerated across all patients. Individual response determines which medication works best, and some patients who struggle with one tolerate the other well.
Medical Disclaimer: This article is for informational purposes only. Medication selection should be made with your prescribing provider based on your individual medical history, goals, and tolerance.
How They Differ Mechanistically
Semaglutide is a pure GLP-1 receptor agonist. It activates one receptor system that controls appetite, gastric emptying, insulin secretion, and glucagon suppression. Tirzepatide is a dual GIP/GLP-1 receptor agonist, activating both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor pathways. For a complete cost breakdown, see our compare tirzepatide pharmacies.
Get provider-reviewed GLP-1 therapy
Side effects are manageable with the right support. A licensed provider can adjust your dose when you need it.
Start Free Assessment →View data table
| Category | Treatment Progress (%) | Detail |
|---|---|---|
| Week 1-2 | 25 | Appetite reduction begins |
| Month 1 | 45 | Nausea subsides, energy improves |
| Month 3 | 70 | Visible weight loss (~5-8%) |
| Month 6 | 85 | Significant results (~10-15%) |
| Month 12 | 95 | Full therapeutic benefit |
The dual mechanism matters for side effects because GIP receptors are distributed differently than GLP-1 receptors. GIP activation may partially buffer some GLP-1-driven GI effects, which some researchers believe explains why tirzepatide can produce greater weight loss with comparable or slightly lower GI side effect rates at certain dose levels.
Both medications slow gastric emptying, suppress appetite, and improve glycemic control. Both produce primarily GI-related side effects. The differences are in degree and character rather than in kind.
Side Effect Comparison Table
Data from SURPASS-2 (Frias et al., NEJM 2021), which compared tirzepatide at three doses against semaglutide 1mg in type 2 diabetes patients.
| Side Effect | Tirzepatide 5mg | Tirzepatide 10mg | Tirzepatide 15mg | Semaglutide 1mg |
|---|---|---|---|---|
| Nausea | 12.2% | 17.4% | 22.7% | 17.9% |
| Diarrhea | 13.7% | 15.9% | 13.2% | 8.5% |
| Vomiting | 2.4% | 5.8% | 8.3% | 8.5% |
| Constipation | 5.4% | 6.0% | 6.8% | 5.8% |
| Decreased Appetite | 5.4% | 7.0% | 9.5% | 4.6% |
| Discontinuation due to AEs | 3.0% | 5.1% | 7.1% | 4.1% |
The table reveals an important nuance. At the lowest tirzepatide dose (5mg), GI side effects are generally lower than semaglutide 1mg. At the highest tirzepatide dose (15mg), some GI side effects are higher. The comparison depends entirely on which dose levels you are comparing.
Nausea: The Detailed Comparison
Nausea rates tell different stories depending on the comparison frame. Tirzepatide 5mg produces meaningfully less nausea (12.2%) than semaglutide 1mg (17.9%). But tirzepatide 5mg also produces less weight loss. At tirzepatide 15mg, which produces more weight loss than semaglutide 1mg, nausea is higher (22.7%).
The duration and pattern of nausea are similar for both medications. Both follow the peak-at-dose-increase, resolve-in-1-to-2-weeks pattern driven by GLP-1 receptor desensitization. Tirzepatide's slower titration schedule (starting at 2.5mg with 2.5mg increases every 4 weeks) may produce a smoother nausea curve compared to semaglutide's larger proportional dose jumps.
FormBlends compounds both medications with flexible dosing options, which allows the smoothest possible titration for either drug. The advantage of compounded formulations is the ability to create intermediate dose steps regardless of which GLP-1 agonist you are using.
GI Profile Differences
Diarrhea is more common with tirzepatide. Across all three tirzepatide doses in SURPASS-2, diarrhea rates ranged from 13 to 16% compared to 8.5% with semaglutide 1mg. The GIP receptor component may drive additional intestinal fluid secretion that contributes to looser stools.
Constipation is similar. Both medications produce comparable constipation rates (5 to 7%). The motility-slowing effects of GLP-1 activation are present in both, and the GIP component of tirzepatide does not appear to offset this. Management strategies for constipation are identical regardless of which medication you take.
Vomiting favors tirzepatide at lower doses. Tirzepatide 5mg produced vomiting in only 2.4% of patients compared to 8.5% with semaglutide 1mg. At tirzepatide 15mg, the rate was comparable (8.3%). The gradual titration schedule likely contributes to lower vomiting rates at entry-level doses.
Switching for Side Effect Reasons
Switching from semaglutide to tirzepatide (or vice versa) for tolerability is a legitimate clinical strategy. The two medications activate overlapping but different receptor systems, and individual variation in receptor expression means some patients tolerate one better than the other.
The switch typically involves stopping the current medication, waiting 1 to 2 weeks for clearance, and starting the new medication at the lowest dose with standard titration. Jumping to an equivalent dose of the new medication is not recommended because cross-tolerance is partial at best.
Community reports of switching are generally positive. Patients who found semaglutide's constipation intolerable sometimes prefer tirzepatide's profile. Patients who experienced significant diarrhea on tirzepatide sometimes do better on semaglutide. The switch is not guaranteed to solve the problem, but it provides a meaningful second option before concluding that GLP-1 agonist therapy is not for you. See our dose comparison article for semaglutide-specific dosing guidance.
Community Reports of Both Medications
r/Mounjaro: "Switched from Ozempic - my side effect comparison"
267 upvotes, 134 comments
A patient documented their experience on semaglutide 1mg for 6 months followed by tirzepatide for 4 months. Nausea was similar on both. Constipation was notably better on tirzepatide. Weight loss was faster on tirzepatide at comparable dose levels. The trade-off was more frequent loose stools. Commenters who had made the same switch reported mixed results, reinforcing that individual response varies significantly between the two medications.
Top comment: "Switched for the constipation. Mounjaro gave me the opposite problem but at least that is easier to manage."
r/Semaglutide: "Tried Mounjaro, came back to Wegovy"
143 upvotes, 88 comments
A patient who switched to tirzepatide for cost reasons found the diarrhea intolerable and returned to semaglutide. The thread highlighted that switching does not always improve the situation. Several commenters noted that they had better appetite suppression on semaglutide despite similar weight loss numbers, suggesting the subjective experience differs between the two medications beyond what clinical endpoints capture.
Top comment: "The appetite suppression feels different. Wegovy makes me forget about food. Mounjaro made me full faster but I still thought about food."
Clinical gap: No head-to-head trial has compared semaglutide 2.4mg against tirzepatide 15mg for both efficacy and tolerability in an obesity-only population. SURPASS-2 used semaglutide 1mg (an Ozempic dose, not the Wegovy maximum) in type 2 diabetes patients. A true max-dose comparison in obesity patients would fundamentally change how providers counsel patients on medication selection.
How to Choose Between Them
The decision between semaglutide and tirzepatide involves side effect profile, insurance coverage, cost, availability, and provider experience. From a pure side effect perspective, neither medication is clearly superior across all patients.
Consider semaglutide if: you have strong appetite suppression as a priority, constipation does not concern you, you prefer a medication with more long-term safety data (semaglutide has been available longer), or your insurance covers Wegovy.
Consider tirzepatide if: you want potentially greater weight loss, constipation on semaglutide was your primary side effect concern, you tolerate diarrhea better than constipation, or your insurance covers Mounjaro/Zepbound.
FormBlends offers both compounded semaglutide and guidance on branded medication options. Your provider can help you evaluate which medication best fits your medical history, side effect concerns, and treatment goals. The right choice is the one you can take consistently.
Frequently Asked Questions
Does tirzepatide have fewer side effects?
At comparable weight loss levels, GI side effect rates are similar. Tirzepatide 5mg has lower nausea than semaglutide 1mg, but tirzepatide 15mg has higher nausea. The profile differs in character more than severity.
Which is better tolerated?
Neither is universally better. Individual variation determines which medication you tolerate. Some patients do better on one than the other.
Can I switch for fewer side effects?
Yes, with provider guidance. Switching involves stopping, waiting 1 to 2 weeks, and retitrating the new medication from the lowest dose.
How do nausea rates compare?
Tirzepatide 5mg: 12.2%. Tirzepatide 10mg: 17.4%. Tirzepatide 15mg: 22.7%. Semaglutide 1mg: 17.9%. Comparison depends on dose level.
Is weight loss different enough to switch?
SURPASS-2 showed greater weight loss with tirzepatide 15mg vs semaglutide 1mg, but this was not a max-vs-max comparison. Weight loss alone may not onlyify switching if your current treatment works.
Do both cause hair loss?
Both can trigger telogen effluvium because hair loss is driven by rapid weight loss, not the specific drug. Management is identical for both.
Medical References
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. [PubMed | DOI]
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →